Atigliflozin

Cat. No.:	HY-14810
CAS No.:	647834-15-9
Molecular Formula:	$C_{18}H_{22}O_7S$
Molecular Weight:	382.43
Target:	SGLT
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC_{50}s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus[1].	
IC_{50} & Target	hSGLT2 10 nM (IC_{50})	hSGLT1 8.2 μM (IC_{50})
In Vivo	AVE2268 (1-300 mg/kg, p.o.) causes a dose-dependent increase of urinary glucose excretion (UGE) in mice and rats[2]. AVE2268 (10-100 mg/kg, p.o.) dose-dependently decreases blood glucose excursions after glucose (i.p. or p.o.) administration in mice[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76.

[2]. Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA